<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091156</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-08021</org_study_id>
    <secondary_id>EORTC-08021</secondary_id>
    <secondary_id>ILCP-01/03</secondary_id>
    <secondary_id>2004-001331-36</secondary_id>
    <nct_id>NCT00091156</nct_id>
  </id_info>
  <brief_title>Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase III Study of Follow Up With or Without Adjuvant Gefitinib (Iressaâ„¢) Following Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for
      their growth. It is not yet known whether giving gefitinib after initial chemotherapy is
      effective in delaying the recurrence of non-small cell lung cancer.

      PURPOSE: This randomized phase III trial is studying gefitinib to see how well it works
      compared to placebo in delaying tumor recurrence in patients who have undergone initial
      chemotherapy for stage IIIB or stage IV non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare overall survival of patients with stage IIIB or IV non-small cell lung cancer
           that did not progress on prior first-line palliative induction chemotherapy when treated
           with adjuvant gefitinib vs placebo.

      Secondary

        -  Compare progression-free survival of patients treated with these regimens.

        -  Determine the safety and toxicity of gefitinib in these patients.

      OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients
      are stratified according to initial disease stage (IIIB vs IV), WHO performance status at the
      end of prior first-line palliative induction chemotherapy (0-1 vs 2), best patient response
      to prior first-line palliative induction chemotherapy (objective response vs stable disease),
      and participating center. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral gefitinib once daily.

        -  Arm II: Patients receive oral placebo once daily. In both arms, treatment continues in
           the absence of disease progression or unacceptable toxicity.

      Patients are followed every 3 months for 2 years and then every 6 months thereafter.

      PROJECTED ACCRUAL: A total of 598 patients (299 per treatment arm) will be accrued for this
      study within 8.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual
  </why_stopped>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by CTC</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">598</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer meeting 1 of the
             following stage criteria:

               -  Stage IIIB

                    -  Pleural fluid and/or supraclavicular nodes allowed provided patient is not
                       eligible for consolidation radiotherapy

               -  Stage IV disease

          -  No disease progression after 2-6 courses of prior platinum-containing first-line
             palliative induction chemotherapy

          -  Brain metastases allowed provided patients are asymptomatic after cranial irradiation
             completed at least 4 weeks ago

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  WHO 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Pulmonary

          -  No history, signs, or symptoms of clinically active interstitial lung disease

               -  Patients with chronic, stable, asymptomatic radiographic changes are eligible

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance and follow-up

          -  No other malignant disease within the past 5 years except basal cell skin cancer or
             adequately treated superficial carcinoma of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent immunotherapy

        Chemotherapy

          -  See Disease Characteristics

          -  Recovered from prior chemotherapy (alopecia allowed)

          -  No concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

        Surgery

          -  Not specified

        Other

          -  No prior epidermal growth factor receptor inhibitors

          -  No concurrent administration of any of the following drugs:

               -  Phenytoin

               -  Carbamazepine

               -  Rifampin

               -  Phenobarbital

               -  Hypericum perforatum (St. John's wort)

          -  No other concurrent anticancer therapy

          -  No other concurrent experimental drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan P. Van Meerbeeck, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Ziekenhuis Gent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghent University</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR - Clinique Saint Joseph - Hopital de Warqueguies</name>
      <address>
        <city>Mons</city>
        <zip>B-7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bank Of Cyprus Oncology Centre</name>
      <address>
        <city>Nicosia</city>
        <zip>2006 Strovolos</zip>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of Egypt</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Livorno</name>
      <address>
        <city>Livorno</city>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Ca'Granda</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Universitaria di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Maggiore Della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale S. Luigi at University of Torino</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Santa Maria Degli Angeli&quot;</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sta. Maria Delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Camillo-Forlanini</name>
      <address>
        <city>Rome</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Maggiore - Borgo Trento</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <zip>6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis - Locatie EG</name>
      <address>
        <city>Haarlem</city>
        <zip>2000</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Cyprus</country>
    <country>Egypt</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP; EORTC Lung Cancer Group and the Italian Lung Cancer Project. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer. 2011 Oct;47(15):2331-40. doi: 10.1016/j.ejca.2011.06.045. Epub 2011 Jul 28.</citation>
    <PMID>21802939</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2004</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

